炎性肠病药物治疗的循证医学研究进展

Advance in Drug Treatment for Inflammatory Bowel Disease from Perspective of Evidence-based Medicine

目的:从循证医学的角度解析炎性肠病药物治疗的相关进展。旨在提高对临床证据的认知,帮助临床医生评估新的治疗,从批判的视角重新看待以往的治疗。方法:收集国外近期相关文献进行评价。结果及结论:炎性肠病(IBD)的发病机制尚不清楚,众多的治疗方案可供选择。因此,循证医学研究结果有非常重要的临床指导意义。IBD的研究方面取得了可喜的进步。但是,有关CD活动指数(CDAI)和临床分型系统仍有待于改进。通过循证医学的研究证据有望确定安全和易于耐受的药物,并能发现目前诊治方面存在的缺陷和问题,更好地解决患者的病痛。

OBJECTIVE： To discuss the advance in drug treatment for inflammatory bowel disease （IBD） from perspective of evidence - based medicine so as to improve clinicians＇ cognition on clinical evidences, help them to evaluate the new treatment and reevaluate the traditional treatment critically, METHODS： We evaluated the recent pertinent literature both at home and abroad. RESULTS ＆ CONCLUSION： The mechanism for IBD remains unknown, yet the treatment regimens available for IBD were numerous. Therefore, the evidence - based research results are of great clinical significance. Great progress has been achieved in the study of IBD, however, Crohn＇s disease activity index （CDAI） and clinical classification system remain to be improved. Based on evidence-based medicine study, safe and tolerable drugs are expected to be decided and defects and problems in the current diagnosis and treatment are likely to be found out for a better relieving of patients＇ pain.